Rani Therapeutics Holdings (RANI) Cash & Equivalents (2020 - 2026)

Rani Therapeutics Holdings' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $9.6 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 4.62% year-over-year to $9.6 million; the TTM figure through Mar 2026 stood at $9.6 million (down 4.62% YoY), while the FY2025 annual figure was $18.6 million, up 394.9% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $9.6 million, down from $18.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $27.2 million in Q3 2022, with the low at $3.8 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $7.6 million (2023), against an average of $10.9 million.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents tumbled 81.73% in 2023, then surged 394.9% in 2025.
• Rani Therapeutics Holdings' Cash & Equivalents stood at $27.0 million in 2022, then slumped by 78.29% to $5.9 million in 2023, then sank by 35.85% to $3.8 million in 2024, then jumped by 394.9% to $18.6 million in 2025, then slumped by 48.2% to $9.6 million in 2026.
• Business Quant data shows RANI's Cash & Equivalents at $9.6 million in Q1 2026, $18.6 million in Q4 2025, and $4.1 million in Q3 2025.